# Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

> **NCT03366688** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 58 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** IBI306
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03366688
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2018-11-05
- **Final completion:** 2018-11-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03366688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03366688, "Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03366688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*